Adriana Ramos
Principal Scientist & Head of Lab Sanofi
Seminars
Thursday 16th April 2026
Translating GLP-1 Agonism to Uncover Novel Mechanisms for Neuroprotection in Alzheimer’s and Parkinson’s Disease
9:00 am
- Investigating how GLP-1-based therapies influence the brain beyond feeding behavior regulation – and their relevance for neurodegenerative disease
- Reconsidering the role of glial cells in mediating therapeutic effects of GLP-1R agonism
- Tracing conserved brain responses to GLP-1 modulation across systems
Thursday 16th April 2026
Fire-Side Discussion: Repurposing GLP-1s to Treat Alzheimer’s & Parkinson’s to Improve Cognitive Function & Reduce Neuroinflammation to Create a New Therapeutic Avenue
12:00 pm
- Diversifying treatment opportunities by investigating GLP-1s for new indications like neurological disorders and addiction to unlock their full therapeutic potential and expand their use beyond cardiometabolic health
- Providing new hope for patients by researching next-generation applications to create therapeutic options for conditions with limited treatments
- Expanding the clinical horizon with a wider range of applications for GLP-1s to establish these therapies as a foundational class of drugs for modern medicine
